PT-141 vs Viagra and Cialis: When Each Works
PT-141 works in the brain; PDE5 inhibitors work in the blood vessels. The mechanism difference determines which patients benefit from which therapy.
Sildenafil (Viagra) and tadalafil (Cialis) revolutionized the treatment of erectile dysfunction. PT-141 (bremelanotide) addresses a different problem entirely. Understanding which mechanism applies to which patient determines whether therapy will work.
How PDE5 inhibitors work
Sildenafil, tadalafil, and vardenafil block phosphodiesterase type 5 in the cavernous tissue of the penis. This amplifies the cGMP signal that produces vasodilation in response to arousal. They are vascular drugs — they require the arousal signal to be present.
How PT-141 works
PT-141 activates melanocortin-4 receptors in the central nervous system, specifically in regions of the hypothalamus involved in sexual desire. It does not act on the vasculature directly. It works whether or not there is an existing arousal signal — because it generates the desire signal itself.
When PDE5 inhibitors are the right choice
Vascular ED — the patient has desire but the mechanical response is insufficient. This is the textbook PDE5 indication. Most men with arousal-dependent ED respond.
When PT-141 is the right choice
Low libido with or without ED. Patients who report "I want to want it, but I don't." Women with hypoactive sexual desire disorder. Men whose ED is desire-driven rather than vascular. PT-141 is the only FDA-approved medication for hypoactive sexual desire disorder in premenopausal women.
Side-by-side comparison
| Feature | PDE5 inhibitors | PT-141 | |---|---|---| | Mechanism | Vascular (peripheral) | Central nervous system | | Indication | Erectile dysfunction | Hypoactive sexual desire | | Onset | 30–60 min | 30–45 min | | Duration | 4 h (sildenafil) – 36 h (tadalafil) | ~24 h | | Notable side effects | Flushing, headache, vision changes | Nausea, flushing, transient BP elevation |
How they can be combined
For patients with both desire and vascular components, the medications can be used together under physician supervision. Combined use requires evaluation of cardiovascular status because both can affect blood pressure transiently.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134:899-908.— Obstetrics and Gynecology, 2019.
- 2.FDA Prescribing Information: Vyleesi (bremelanotide) injection.— U.S. Food and Drug Administration, 2019.
- 3.Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide. J Sex Med. 2006;3:628-638.— Journal of Sexual Medicine, 2006.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
